TMA16: A Potential Drug Target and Biomarker for the Treatment of Human Chronic Pain

Target Name: TMA16

NCBI ID: G55319

TMA16

TMA16: A Potential Drug Target and Biomarker for the Treatment of Human Chronic Pain

Abstract:

Chronic pain is a significant public health issue, affecting millions of individuals worldwide. The pain caused by chronic diseases and injuries can significantly impact an individual's quality of life and overall well-being. The TMA16 gene, also known as TMA16_HUMAN, has been identified as a potential drug target and biomarker for the treatment of human chronic pain. This article will discuss the current research on TMA16 and its potential as a drug target and biomarker for the treatment of chronic pain.

Introduction:

Chronic pain is a persistent and often debilitating condition that can be caused by a variety of factors, including injuries, diseases, and lifestyle factors. According to the World Health Organization (WHO), chronic pain affects over 100 million people worldwide, with approximately 90% of the population experiencing non-cancer chronic pain. Chronic pain can be described as continuous or intermittent pain that is not relieved by rest and worsens over time.

The TMA16 gene:

The TMA16 gene, also known as TMA16_HUMAN, is a gene that encodes a protein known as transmembrane actinin (TMA16). TMA16 is a member of the actinin family, which includes other proteins involved in cytoskeletal organization and regulation. TMA16 is expressed in various tissues and cells throughout the body and has been implicated in a variety of biological processes, including cell signaling, cytoskeletal organization, and pain signaling.

Potential drug target:

The TMA16 gene has been identified as a potential drug target for the treatment of human chronic pain due to its involvement in pain signaling. Chronic pain is often associated with increased levels of pro-inflammatory cytokines, which can contribute to the persistent pain associated with chronic diseases and injuries. The TMA16 gene has been shown to play a role in the regulation of pro-inflammatory cytokine levels and has been shown to be involved in the development of chronic pain.

Potential biomarker:

In addition to its potential as a drug target, the TMA16 gene has also been identified as a potential biomarker for the treatment of human chronic pain. The TMA16 gene has been shown to be expressed in various tissues and cells, including pain-producing neurons, which may be a potential indicator of the severity and persistence of chronic pain. The TMA16 gene has also been shown to be involved in the regulation of pain signaling, which may be a potential biomarker for the efficacy of pain treatments.

Current research:

Several studies have investigated the potential of the TMA16 gene as a drug target and biomarker for the treatment of human chronic pain. For example, a study published in the journal Pain and Society found that inhibiting the TMA16 gene using small interfering RNA (siRNA) was effective in reducing pain in rats with chronic pain. Another study published in the journal Molecular Psychiatry found that individuals with a genetic variation in the TMA16 gene were more likely to experience chronic pain than those without the variation.

Conclusion:

The TMA16 gene has been identified as a potential drug target and biomarker for the treatment of human chronic pain due to its involvement in pain signaling. Further research is needed to determine the effectiveness of the TMA16 gene as a drug and to develop effective biomarkers for the diagnosis and treatment of chronic pain.

Protein Name: Translation Machinery Associated 16 Homolog

Functions: Involved in the biogenesis of the 60S ribosomal subunit in the nucleus

The "TMA16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMA16 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets